Lung cancer stands as a formidable health challenge, claiming more lives globally than any other type of cancer. This ...
Visugromab combined with nivolumab showed a median duration of response exceeding two years in refractory NSCLC, UC, and HCC patients. GDF-15 is a therapeutic target and immune escape mechanism, ...
One of the biggest challenges in cancer treatment is something called “drug resistance.” This happens when cancer cells stop ...
We all know that cancer risk generally increases with age, but did you know that at a very advanced age, this trend might ...